Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia

[Guest guest]

BlankModulation of IL-4 level by fludarabine and its relation to apoptosis in

chronic B-cell lymphocytic leukemia.

LA Shamaa, Ael-S Hussein, OA Balbaa, NM Farahat, and MA Ali

Egypt J Immunol, January 1, 2008; 15(1): 181-92.

Immunology Department, Medical Research Institute, andria University, Egypt.

Accumulation of malignant B-lymphocytes in chronic B-cell lymphocytic leukemia

(B-CLL) is mainly attributed to reduced apoptosis rather than increased

proliferation rate. Interleukin-4 (IL-4) has been proved to be involved in the

survival mechanisms of B-cells as well as protection of B-CLL cells against

spontaneous or drug induced apoptosis. Fludarabine is one of purine analogs and

the current standard treatment for B-CLL, which has been proved to induce

apoptosis in normal and malignant lymphocytes. We investigated the effect of ex

vivo treatment of peripheral blood lymphocytes (PBLs) with Fludarabine on

apoptosis and IL-4 production in untreated patients with B-CLL. The study was

conducted on 15 recently diagnosed B-CLL patients and 15 normal healthy control

subjects. PBLs were isolated and cultured in complete culture media without and

with the addition of 1 microM/ml Fludarabine for 48 hrs. Harvested cells were

assessed by flowcytometry for apoptosis and IL-4 production using staining with

Annexin-V/PI and specific monoclonal IL-4 antibody, respectively. Results:

Fludarabine significantly increased the rate of in vitro PBLs' apoptosis in both

B-CLL patients and normal subjects (3.81 +/- 1.98% and 4.11 +/- 2.14% without

Fludarabine vs 14.78 +/- 7.83% and 9.99 +/- 5.60% with Fludarabine,

respectively). However, the cytotoxic effect of Fludarabine was significantly

higher in B-CLL patients than normal control subjects. Cytolasmic IL-4 content,

as reflected by mean flouresence intensity (MFI), as well as percentage of

IL-4+ve PBLs in absence Fludarabine were nearly the same both in B-CLL patients

(20.28 +/- 14.34 & 2.97 +/- 1.48%, respectively) and normal subjects (27.75 +/-

14.44 & 2.58 +/- 1.27% respectively), with no significant difference.

Corresponding values were significantly increased in both B-CLL patients (34.46

+/- 22.95 & 15.08 +/- 8.17%, respectively) and normal subjects (40.15 +/- 17.11

& 17.05 +/- 8.74%, respectively) when PBLs were co-cultured with Fludarabine.

However, no significant difference was observed when studied groups were

compared to each other. No correlation was observed between the intracellular

IL-4 content or percentage of IL-4+ve PBLs and Fludarabine-induced apoptosis. In

conclusion, Floudarabine could induce apoptosis and IL-4 production in B-CLL

patients. Further studies on large cohort population is recommended to clarify

the apoptotic effect of Fludarabine.

PMID: 20306682

----------

No virus found in this outgoing message.

Checked by AVG - www.avg.com

Version: 8.5.437 / Virus Database: 271.1.1/2779 - Release Date: 03/30/10

06:32:00